Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL419376 | 0.87 | GAA (0.66) | NPSR1GAAALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL12290360 | 0.84 | GAA (0.51) | NPSR1GAAALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL2412870 | 0.84 | MAPT (0.61) | NPSR1GAAALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL4419517 | 0.84 | MAPT (0.53) | NPSR1GAAALDH1A1KDM4EPOLB | |
| SCHEMBL6064895 | 0.84 | TSHR (0.52) | NPSR1GAAALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL7903369 | 0.83 | PLA2G4B (0.69) | NPSR1GAAKDM4EPLA2G4BTP53 | |
| SCHEMBL13382671 | 0.83 | POLB (0.54) | ALDH1A1KDM4ESMN1; SMN2POLBTSHR | |
| SCHEMBL6092006 | 0.82 | MAPT (0.60) | NPSR1GAAALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL28532238 | 0.78 | NPSR1 (0.51) | NPSR1GAAKDM4EMAPTKMT2A | |
| SCHEMBL12098274 | 0.78 | RAB9A (0.59) | NPSR1GAAALDH1A1POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100189648-A1 | INHIBITORS FOR DISRUPTING THE INTERACTION OF UBIQUITINATION RELATED ENZYMES AND USES THEREOF | HUANG LAN | 2010-07-29 | — | — | US | disclosed |
| US-20100189648-A1 | INHIBITORS FOR DISRUPTING THE INTERACTION OF UBIQUITINATION RELATED ENZYMES AND USES THEREOF | HUANG LAN | 2010-07-29 | — | — | US | disclosed |
| US-6441189-B1 | WHICH REDUCES RACEMIZATION; (4R)-4-(HYDROXYMETHYL)-1,3-OXAZOLIDIN-2-ONE BY REDUCTION AND BASIFICATION OF THE CORRESPONDING 4-PROTECTED CARBOXY ESTER | ABBOTT LABORATORIES | 2002-08-27 | — | — | US | disclosed |
| US-20020052511-A1 | Process for the preparation of matrix metalloproteinase inhibitors | BAILEY ANNE E (US) | 2002-05-02 | — | — | US | disclosed |
| US-20020019539-A1 | Process for the preparation of matrix metalloproteinase inhibitors | ABBOTT LABORATORIES | 2002-02-14 | — | — | US | disclosed |
| WO-2001074792-A2 | PROCESS FOR THE PREPARATION OF MATRIX METALLOPROTEINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2001-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052511-A1 | Process for the preparation of matrix metalloproteinase inhibitors | MMP9, TIMP3, MMP2 | NPSR1 1646/4885GAA 314/4885ALDH1A1 1359/4885 |
| US-20020019539-A1 | Process for the preparation of matrix metalloproteinase inhibitors | MMP9, TIMP3, MMP2 | NPSR1 1646/4885GAA 314/4885ALDH1A1 1359/4885 |
| US-20100189648-A1 | INHIBITORS FOR DISRUPTING THE INTERACTION OF UBIQUITINATION RELATED ENZYMES AND USES THEREOF | MDM2, UBE2N, UBE2E1 | NPSR1 4628/4885GAA 354/4885ALDH1A1 1796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.